UBS Group
ONCT

UBS Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

UBS Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,221
Closed -$1.61K – 10775
2024
Q3 		$1.61K Buy
1,221
+1,121
+1,121% +$5.41K ﹤0.01% 8595
2024
Q2 		$760 Hold
100
– – ﹤0.01% 8781
2024
Q1 		$900 Hold
100
– – ﹤0.01% 8314
2023
Q4 		$1.07K Sell
100
-579
-85% -$4.17K ﹤0.01% 8410
2023
Q3 		$4.08K Buy
679
+178
+36% +$1.25K ﹤0.01% 7477
2023
Q2 		$3.46K Buy
501
+298
+147% +$1.97K ﹤0.01% 7627
2023
Q1 		$3.18K Sell
203
-35
-15% -$689 ﹤0.01% 8361
2022
Q4 		$4.76K Sell
238
-594
-71% -$11.8K ﹤0.01% 9279
2022
Q3 		$15K Sell
832
-7,483
-90% -$160K ﹤0.01% 7852
2022
Q2 		$184K Buy
8,315
+7,751
+1,374% +$173K ﹤0.01% 4996
2022
Q1 		$16K Sell
564
-675
-54% -$24.6K ﹤0.01% 7774
2021
Q4 		$56K Sell
1,239
-7,066
-85% -$475K ﹤0.01% 6806
2021
Q3 		$692K Buy
8,305
+1,183
+17% +$97.9K ﹤0.01% 4494
2021
Q2 		$677K Buy
7,122
+6,958
+4,243% +$826K ﹤0.01% 4503
2021
Q1 		$27K Buy
+164
New +$21.7K ﹤0.01% 7111
2020
Q4 		– Sell
-193
Closed -$7K – 8898
2020
Q3 		$7K Buy
+193
New +$9.46K ﹤0.01% 7156
2020
Q2 		– Sell
-5
Closed – – 8482
2020
Q1 		$0 Sell
5
-16
-76% -$1.19K ﹤0.01% 8548
2019
Q4 		$1K Sell
21
-60
-74% -$6.21K ﹤0.01% 7999
2019
Q3 		$8K Sell
81
-11
-12% -$1.13K ﹤0.01% 7300
2019
Q2 		$13K Buy
92
+57
+163% +$8.8K ﹤0.01% 6914
2019
Q1 		$6K Sell
35
-41
-54% -$6.12K ﹤0.01% 7113
2018
Q4 		$8K Buy
76
+27
+55% +$5.4K ﹤0.01% 7371
2018
Q3 		$11K Buy
49
+41
+513% +$98.4K ﹤0.01% 7132
2018
Q2 		$18K Buy
8
+3
+60% +$7.61K ﹤0.01% 6787
2018
Q1 		$11K Sell
5
-4
-44% -$8.91K ﹤0.01% 6824
2017
Q4 		$17K Buy
9
+4
+80% +$5.79K ﹤0.01% 6687
2017
Q3 		$5K Hold
5
– – ﹤0.01% 7247
2017
Q2 		$3K Sell
5
-17
-77% -$10.4K ﹤0.01% 7314
2017
Q1 		$15K Buy
22
+1
+5% +$733 ﹤0.01% 6360
2016
Q4 		$15K Buy
21
+16
+320% +$17.1K ﹤0.01% 6694
2016
Q3 		$5K Hold
5
– – ﹤0.01% 7144
2016
Q2 		$4K Hold
5
– – ﹤0.01% 7257
2016
Q1 		$3K Sell
5
-1
-17% -$867 ﹤0.01% 7221
2015
Q4 		$6K Buy
6
+1
+20% +$1.32K ﹤0.01% 7636
2015
Q3 		$5K Hold
5
– – ﹤0.01% 7741
2015
Q2 		$9K Sell
5
-13
-72% -$18.5K ﹤0.01% 7558
2015
Q1 		$17K Buy
18
+8
+80% +$7.95K ﹤0.01% 7164
2014
Q4 		$11K Buy
+10
New +$8.93K ﹤0.01% 8335

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

UBS Group's ONCT Position: Q4 2024 in Review

UBS Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 1,221 shares — an estimated $1.61K sold.

UBS Group first reported a position in ONCT in Q4 2014 and held it in 38 quarters. The position peaked at $692K in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • UBS Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 1,221 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $1.61K.
  • UBS Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2014 and held it in 38 quarters.
  • UBS Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $692K in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.